Eiger BioPharmaceuticals (EIGR) Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surge Jun 13, 2022 08:10AM
Eiger BioPharmaceuticals (EIGR) Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19, No Difference in Duration of SARS-CoV-2 Viral Shedding Sep 28, 2020 08:04AM
Eiger BioPharmaceuticals (EIGR) Reports Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia Oct 16, 2018 04:06PM
Eiger BioPharmaceuticals (EIGR) Reports Complete Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients Jan 4, 2018 08:05AM
Eiger BioPharmaceuticals (EIGR) Announces Results Demonstrating Benefit of Ubenimex and LTB4 Modulation in Experimental Lymphedema May 17, 2017 08:03AM


May 15, 2017 08:06AM Eiger BioPharmaceuticals (EIGR) Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in PAH
Jan 3, 2017 08:10AM Eiger BioPharmaceuticals (EIGR) First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in PAH
Jul 25, 2016 08:15AM Eiger BioPharmaceuticals (EIGR) Doses First Patient in Ubenimex Phase 2 as Secondary Lymphedema Treatment
Jun 13, 2016 08:02AM Eiger BioPharmaceuticals (EIGR) Reports Positive Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with PBH